Apart from tightening the approvals process for pharmaceutical products meant for overseas markets, the government’s efforts are also directed at strengthening drug exports
India s drug regulator withdraws state licensing authorities NOC issuance power for export of unapproved drugs due to substandard products overseas. Industry to reapply via zonal offices online from May 15. Contaminated cough syrups linked to acute kidney injuries in Gambian children.
Sanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 receptor agonist lixisenatide. The medication is available at a therapy cost of Rs 1,850 per pen and is indicated for adults with obesity and type 2 diabetes to improve glycemic control.
Supreme Court addresses misleading ads, pending amendments to DMR(OA) Act since Feb 2020 with Union health ministry. Proposed changes aim to enhance penalties for prohibited drug ads. Complaints against Patanjali under DMRA.
The code prohibits pharma companies from organising overseas workshops for healthcare professionals or providing them with accommodations, extravagant meals, or financial incentives